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Modulatory Effects of Pregnancy on Inflammatory
Bowel Disease
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The disease course of autoimmune diseases such as rheumatoid arthritis is altered during pregnancy, and a similar
modulatory role of pregnancy on inflammatory bowel disease (IBD) has been proposed. Hormonal, immunological, and
microbial changes occurring during normal pregnancy may interact with the pathophysiology of IBD. IBD consists of
Crohn’s disease and ulcerative colitis, and because of genetic, immunological, andmicrobial differences between these
disease entities, theymay react differently duringpregnancy and should bedescribed separately. This reviewwill address
the pregnancy-induced physiological changes and their potential effect on the disease course of ulcerative colitis and
Crohn’s disease, with emphasis on the modulation of epithelial barrier function and immune profiles by pregnancy
hormones, microbial changes, and microchimerism.
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INTRODUCTION
Inﬂammatory bowel disease (IBD), comprising Crohn’s disease
(CD) and ulcerative colitis (UC), is a group of chronic diseases of
the gastrointestinal tract that aﬀects men and women in their
reproductive years of life. IBD and IBD therapies can have an
impact on fertility, pregnancy outcomes, and fetal/neonatal
health. Vice versa, the changes in hormones and in the immune
system that occur during pregnancy may also inﬂuence IBD
activity.
There is a clear link between the female reproductive cycle and
the gastrointestinal tract, as demonstrated by several studies
reporting an increase in gastrointestinal symptoms among
womenwith IBD and irritable bowel syndrome before and during
the menstrual period (1,2) and in changes to the menstrual
function among women with IBD (3). Physiological changes that
occur during the menstrual period include changes in hormones,
cytokines, and immune proﬁles, whichmay aﬀect gastrointestinal
motility, inﬂammation, and sensitivity (4). Similar changes also
occur during pregnancy, and a modulatory role of pregnancy on
inﬂammatory disease behavior has therefore been the topic of
research for many years. The most convincing amelioration of
(auto)inﬂammatory disease during pregnancy is observed in
rheumatoid arthritis (RA), where symptoms abate during preg-
nancy, and ﬂares are commonly observed postpartum (5,6).With
many of the underlying pathogenic mechanisms (genetics, in-
testinal microbiome alterations, and immune shifts) overlapping
with IBD, resulting in several shared treatment options (7–9), it is
not surprising that a disease modulatory role for pregnancy in
IBD has also been speculated upon. Nevertheless, conﬂicting
results of the eﬀect of pregnancy in IBD have been observed. One
study showed that patients with both CD and UC experienced
fewer ﬂares in the 3 years postpartum as compared to their ﬂare
rate before pregnancy (10). A 10-year follow-up study conﬁrmed
that relapse rates decreased in UC (from 0.34 to 0.18 ﬂares per
year) and CD (from 0.76 to 0.12 ﬂares per year) after pregnancy
(11). In addition, it appears safe to stop anti–tumor necrosis
factor alpha (TNF-a) treatment in pregnant patients with IBD,
without increasing the risk of ﬂares (12,13). However, these data
are disputed by a study of Pedersen et al. (14), who showed that
pregnant women with CD have a similar disease course during
and after pregnancy as compared to nonpregnant women with
CD. In contrast, women with UC have a higher risk of relapse
during pregnancy (relative risk (RR) 2.19) and postpartum (RR
6.22), compared to nonpregnant women with UC. The course of
IBD activity during pregnancy is closely related to disease activity
preconception (15), with women who conceive during a time of
active disease having twice the risk (RR 2.0) of disease ﬂare during
pregnancy compared to those who conceive during a time of
remission. Although the often-reported medication non-
adherence during pregnancy may be a confounding factor (16),
disease course during pregnancy appears to be related to the type
of IBD, suggesting a true relationship between pregnancy and
disease activity.
In this review, we summarize the current knowledge re-
garding the interaction between reproductive physiology and
IBD pathophysiology, and propose explanations for the clinical
observations of IBD behavior during the reproductive period.
We describe the pathological alterations in barrier function,
immunology, and microbiome in IBD and discuss how these
factors are modulated during pregnancy. A better un-
derstanding of these complex interactions and clinical obser-
vations will aid clinicians and researchers in improving the
management of IBD during pregnancy, and optimize maternal
and neonatal outcomes.
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PATHOGENESIS OF IBD
IBD is a multifactorial disease, in which an altered immune re-
sponse toward the intestinal microﬂora results in chronic in-
ﬂammation of the intestinal tract. In addition to environmental
factors (hygiene, smoking, diet, etc.), genetic susceptibility plays
an important role in IBD, and large genome-wide association
studies have identiﬁed more than 200 genetic loci associated with
an increased risk of developing IBD (17,18). Interestingly,
attempts at identifying common underlying mechanisms based
on these loci have uncovered an important role for (innate) im-
munity and bacterial handling in IBD susceptibility: Many of the
identiﬁed risk genes can be classiﬁed in pathways aﬀecting epi-
thelial barrier function, innate immune cell function, or adaptive
immunity. All of these processes are critical at the contact in-
terface between host and bacteria, underscoring the importance
of these interactions in IBD development (18).
Epithelial barrier function in IBD
The ﬁrst obstacle for bacterial invasion is represented by the in-
testinal epithelial barrier, which, although not traditionally
regarded as part of the immune system, is now gaining recogni-
tion as part of the ﬁrst-line innate immune defense. Bacteria are
physically separated from the actual barrier cells through the
production of a mucous layer and the release of antimicrobial
peptides, therein, by goblet cells and Paneth cells, respectively.
Disease predisposing genetic variants in mucin genes may con-
tribute to alterations in themucus layer in patients with IBD (19).
With the mucosal layer breached, bacterial components have an
increased chance to reach the epithelial cell layer. In response,
diﬀerent immune cells at the mucosa/luminal interface produce
inﬂammatory cytokines, such as interferon gamma (IFN-g) and
TNF-a, which can inhibit antiapoptotic proteins and promote
apoptotic processes, resulting in a weakening of the epithelial
lining and an increased translocation of pathogens (20). This
process, referred to as “leaky gut,” is already seen in healthy ﬁrst-
degree relatives of patients and therefore appears to be one of the
disease initiating events in patients with IBD. Barrier dysfunction
is worsened during active disease, when there is an additional
reduction in tight junctions, which regulate the epithelial per-
meability (21). Thus, the overall weakening of the barrier function
in IBD results in an enhanced exposure of themucosa to bacterial
components, which stimulates the attraction of immune cells and
perpetuates inﬂammation.
Epithelial barrier function during pregnancy
Female reproductive hormones ﬂuctuate during the normal
menstrual cycle, with estrogen reaching peak levels before ovu-
lation and progesterone reaching peak levels during the luteal
phase of the cycle. Fluctuations of these hormones even on estrus
scale already appear to aﬀect bowel health. The gut epithelium
expresses receptors for both estrogen (estrogen receptor a and b)
and progesterone (22), and data in animal models show that
paracellular permeability is decreased during the estrogen dom-
inant phase of the cycle as compared to the progesterone domi-
nant phase, consistent with an improved barrier integrity in
response to estrogen (23). Gut epithelial cells in female rats are
also more resistant to injury and inﬂammation than in male rats,
and application of estrogen to male gut cells abrogates the en-
hanced inﬂammatory susceptibility in these male cells (24).
Furthermore, progesterone receptor expression is increased in
constipated persons, suggesting that even though progesterone
does not have a direct eﬀect on barrier integrity (23), it may aﬀect
ion and water transport in the gut (25).
With these relatively small systemic ﬂuctuations in hormone
levels already impacting epithelial barrier function in an anti-
inﬂammatory and diarrhea-reducing manner, it is tempting to
speculate that similar actions on a larger scale take place during
pregnancy. Estrogen and progesterone levels increase rapidly
during the ﬁrst trimester, causing some of the nausea women
experience. Estrogen peak levels are reached during the third
trimester, accounting for the vascularization of the placenta and
uterus, supporting the development of the fetus and the de-
velopment of the milk duct. Interestingly, although low levels of
17 beta-estradiol (17b-EE) decreased paracellular permeability of
vascular endothelial cells, high levels of EE increased the per-
meability, as a result of biphasic modulation of the tight junction
molecule occludin (26). Thus, although epithelial barrier function
has not been investigated during pregnancy, it is possible that
studies performed during estrus are not reﬂective of a protective
role of estrogen during pregnancy. Nevertheless, in irritable
bowel syndrome, a link between increased gastrointestinal
symptoms at the lowest estrogen levels of themenstrual cycle and
reduced complaints during pregnancy is suggestive of a positive
eﬀect of pregnancy hormones on intestinal health (27).
IMMUNITY IN IBD
Innate immunity
The immune system represents a complex interplay of diﬀerent
cell types aimed at defending the human body from pathogenic
microorganisms. Innate immunity is the ﬁrst-line defense of the
body against infections and includes monocyte/macrophages,
granulocytes, and dendritic cells (DCs) (Table 1). These cells,
constitutively present in body tissues, act as sentinels of the body
by indiscriminate uptake (phagocytosis) and digestion of
pathogens. Increased numbers of granulocytes, macrophages,
and DCs have been observed in intestinal lesions in IBD. These
cells may contribute to exacerbation of disease by releasing
damaging reactive oxygen species and increasing local proin-
ﬂammatory cytokine levels. An inherent alteration in bacterial
responses of these cells appears to be present in IBD, which may
contribute to the pathogenesis (28–30). For instance, macro-
phages from patients with IBD show increased proinﬂammatory
and decreased anti-inﬂammatory cytokines when stimulated
with bacteria (31). Epithelial wound healing in colitis models
requires the presence of specialized M2 macrophages (32,33),
which, in contrast to proinﬂammatory M1 macrophages, release
anti-inﬂammatory interleukin 10 (IL-10) and contribute to tissue
remodeling. Inmucosa from patients with IBD, a shift towardM1
macrophages at the expense ofM2macrophages is observed (34),
which may contribute to an impaired mucosal healing and pro-
longed inﬂammation.
Adaptive immunity
Presentation of pathogenic antigens on the cell surface of DCs
and macrophages cells in the context of major histocompatibility
complex (MHC) II molecules can subsequently activate cells of
the adaptive immune system, in particular CD41 T-helper cells
(Th cells). On antigen stimulation, T cells diﬀerentiate into dif-
ferent subsets, depending on the local cytokine milieu. These
include Th1, Th2, Th17, and regulatory T cells (Tregs), which
each fulﬁll diﬀerent functions and produce diﬀerent cytokines.
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Table 1. Changes of the immune system during pregnancy and IBD
Cell type Subtype Function Changes in IBD Changes during pregnancy Conceivable effect of changes
during pregnancy on IBD
Epithelial barrier Goblet cells
Paneth cells
Production of a mucous layer
Release of antimicrobial
peptides
Decrease of mucus layer in IBD
Decrease of antimicrobial
peptides in IBD
Improved barrier integrity in
response to estrogen
Positive effect, mainly due to
increase estrogen
Innate immune system;
adaptive immune system
Monocytes Macrophages
and
dendritic cells
(DCs)
Phagocytosis and
digestion of pathogens
Antigen presentation and
activation of the adaptive
immune system
DCs express IDO1, which
induces apoptosis of
CD81 T cells and
promotes differentiation of
CD41 T
cells to Tregs
Increased in IBD
Skewing of macrophages
from M2 (important
for wound healing) to M1
(inflammatory) phenotype
Decrease from early
pregnancy to mid-gestation
Skewing toward M2 wound
healing macrophages at
placental interface
Fetal tolerance via Tregs
Positive effects through
circulating M2 macrophages
and Tregs and their cytokines
Granulocytes Phagocytosis and
digestion of pathogens
Release a number of
different effector
molecules at site of
infection
Increased in IBD Decrease from early
pregnancy to mid-gestation
Decrease during pregnancymay
have a positive effect on IBD
course
Natural killer (NK)
cells
Secrete cytokines such
as IFN-g and TNF-a,
which act on macrophages
and DCs
Ability to kill tumor cells
without any priming or
prior activation
Increased in CD Increase of placental and
decidual NK cells
Local effect during pregnancy,
so probably no influence on the
course of IBD
Innate lymphoid cells
(ILCs)
ILC1 (IFN-g,
TNF-a)
ILC2 (IL-4, IL-5,
IL-9, IL-13)
ILC3 (IL-17,
IL-22, TNF-a)
Secrete immunoregulatory
cytokines
ILC1 increased in CD
ILC2 increased in IBD
ILC3 increased in IBD
First trimester: Increase of
ILC1 and ILC3
Negative effect on CD,
potentially beneficial effect on
UC
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Table 1. (continued)
Cell type Subtype Function Changes in IBD Changes during pregnancy Conceivable effect of changes
during pregnancy on IBD
T cells T-helper 1
(Th1) (IL-2,
IL-12, IFN-g,
TNF-a)
T-helper 2 (Th2)
(IL-4, IL-5,
IL-6, IL-9,
IL-10, IL-13)
T-helper 17
(Th17) (IL-17,
IL-21, IL-22)
Regulatory
T cells (Tregs)
(TGF-b, IL-35,
IL-10)
Cytotoxicity, antitumor and
antiviral responses
Antibody mediated immunity
by stimulating B cells
Protect cell surfaces by
removing extracellular
bacteria
Regulate the function of
other T-cell subsets and
thereby repress
inflammatory processes
Increased in CD
Increased in UC
Increased in UC
Increased in IBD
First trimester: Increased
in local tissue
Second/third trimester:
Increase in local tissue
Second trimester: Increased
UC more likely to flare during
pregnancy
CD, not UC,may benefit from the
shift to Th2 phenotype
Unclear
Hormones HCG Mediates early expansion of
Tregs
Modulates DC responses by
inducing IDO1 expression
Reduces inflammatory
cytokines such as IL-17 while
increasing IL-10 levels
In vitro, hCG is able to stimulate
peripheral blood DC subsets to
maintain a tolerant phenotype
Increase in first trimester HCG or its peptides may
contribute to the amelioration of
inflammatory processes
Progesterone Decrease of proinflammatory
mediators (i.e., TNF-a, IL-6, IL-
1b, NO)
Increases IL-10 production by
macrophages and monocytes
Increase during pregnancy,
with a decrease before labor
Conflicting data
Estrogen Decreases inflammatory
cytokine production (i.e., TNF-a
and IFN-g)
Inhibits NO synthase activity
Decreases the recruitment of
inflammatory cells
Increase during pregnancy Conflicting data in animal
studies and human studies
regarding contraceptive use
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Distinct cytokine expression diﬀerences and T-cell subset activ-
ities have been observed between patients with CD and UC (35),
and an overactivation of the adaptive immune response with
mucosal inﬁltrating T cells is evident, with the eﬀectivity of tar-
geted therapies against T cells underscoring the importance of
this cell compartment in disease activity. Although IFN-g and IL-
17A cytokine expression, representative of Th1 and Th17 cells,
respectively, are increased the lamina propria in CD, the Th2
cytokines IL-4, IL-5, and IL-13 are increased in UC (36). Under
normal circumstances, Th1 and Th2 cells are in a dynamic
equilibrium, with an imbalance resulting in either Th1 or Th2
dominant diseases. Although a gross simpliﬁcation, CD is now
generally regarded as a Th1/Th17 disease, whereas UC is con-
sidered as a Th2/Th17 disease.
Tolerance
Of course, with the number of bacteria being equal to the
number of human cells in the body (37), it is imperative that the
immune system does not respond to all bacteria present. Im-
mune tolerance development is therefore key to a successful
symbiosis with our commensal microﬂora and is largely medi-
ated by Tregs, which suppress T-cell activation through pro-
duction of cytokines such as IL-10 and transforming growth
factor b (38). In addition, on IFN-g stimulation, DCs express
the enzyme indoleamine 2,3,-dioxygenase (IDO1), which con-
verts the essential amino acid tryptophan into kynurenine. This
has the dual eﬀect of inducing apoptosis of CD81 T cells by
tryptophan depletion, and skewing CD41 T cells to Treg dif-
ferentiation (39,40). Although theoretically it might be expected
that regulatory T-cell functions would be decreased in intestinal
inﬂammation, the reverse has been observed: In IBD, both the
number of Tregs and their diﬀerentiation-inducing agent IDO1
are increased in mucosal IBD biopsies compared to patients
with non-IBD (41,42). In part, this seems a (failed) compensa-
tory mechanism, with Tregs from the peripheral blood being
recruited to inﬂamed mucosal area (42). Nevertheless, many
experimental models show the beneﬁts of redirecting the
Th/Treg balance and suggest that Tregs may be a suitable target
for treatment (43). Phenotypic alterations associated with re-
duced tolerance induction have also been observed for DCs and
macrophages in IBD (44,45).
Innate lymphoid cells
In addition to innate myeloid cells, a family of lymphoid-derived
cells with innate properties exists, which includes natural killer
(NK) cells and a relatively recently identiﬁed subset of cells called
innate lymphoid cells (ILCs) (46) (Table 1). These cells are
enriched at the intestinal mucosa, but unlike “real” lymphocytes,
they do not require antigen recognition in MHC II context, but
rather rely onmyeloid-derived cytokines and natural cytotoxicity
receptors for their activation (47). Increased numbers of IL-17
and IFN-g producing NK cells and ILCs have been observed in
mucosal biopsies from patients with CD (48,49), but not from
patients with UC (50). Although several experimental models
have now highlighted the importance of ILCs for IBD pathology
(reviewed in (51)), and NK cell populations are a target for
treatments such as 6-mercaptopurine and azathioprine (48,52),
cytokine disturbances in IBD have traditionally been linked to
a skewing in adaptive immune responses, in particular those
represented by Th-cell subsets.T
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Immunity during pregnancy
Many excellent reviews have already been written on the im-
munological changes taking place during pregnancy (53–56), the
main ﬁndings of which are summarized here.
During pregnancy, an MHC mismatched fetus is present in
themother, which, despite the presence of a placental barrier, still
aﬀects thematernal immune system. Thus, induction of tolerance
against paternal antigens appears to lay at the heart of immu-
nological changes in successful pregnancies. Immune cells in-
ﬁltrate the placenta during pregnancy, around 70% of which
consists of NK cells. Unlike peripheral NK cells, placental NK
cells are not cytotoxic, but help decidualization, angiogenesis,
immune tolerance, and fetal development by producing growth
factors (57,58). Decidual NK cells may possess both immune-
activating and regulatory properties (59), and although their
presence is beneﬁcial during early pregnancy, their persistence or
failure to switch to a diﬀerent phenotype in later pregnancy is
associated with adverse pregnancy outcomes (60,61).
The remainder of placental immune cells consists mostly of
macrophages and T cells, including Tregs. Macrophages in the
decidua show a distinctM2 phenotype and are amajor source of
placental anti-inﬂammatory IL-10 and show reduced T cell-
activating properties compared to their peripheral blood
counterparts (62). They (as well as DCs and trophoblasts) are
an important source of the soluble IDO1 enzyme, which con-
tributes to the generation of Tregs and establishment of fetal
tolerance (63). It has been postulated that a shift from in-
ﬂammatory Th1 to more permissive Th2 cytokine proﬁles is
required for a successful pregnancy (64,65). IL-25, an IL-17
family member expressed by decidual T-cells, NK cells, Tregs,
and macrophages, stimulates the production of IL-4 and IL-10
in decidual T cells, thereby contributing to a Th2 environment
in ﬁrst-term placentas (66). Furthermore, human term pla-
centas show increased levels of Th2 cytokines compared to
preterm placentas (67,68). However, it is increasingly accepted
that a healthy pregnancy depends on the maternal immune
system to adapt to the diﬀerent stages of pregnancy, and that
proinﬂammatory processes are also required for the tissue
remodeling, which is essential for decidua formation and labor
induction (53). For instance, despite the presence of IL-10, the
ﬁrst trimester of pregnancy is also characterized by the presence
of a proinﬂammatory Th1 immune proﬁle for the successful
implantation of the blastocyst, and IL-6, IL-8, and TNF-a are
present at the implantation site (55). The source of these
cytokines may be Th1 cells (69), although ILC1 and specialized
ILC3 cells have also been observed in ﬁrst-term placentas (70).
Cell subsets shift during pregnancy, with the presence of
macrophages declining from early to mid gestation, whereas T-
cell frequencies increase during this time interval (71). Term
labor and delivery appears to require low-level, well-controlled
inﬂammatory processes (72). Correspondingly, placental IL-10
levels decrease toward labor (73), and rat models indicate an
increase IL-6, TNF-a, and IL-1b in term placentas (74).
In toto, the current general consensus suggests that implan-
tation requires a Th1 response, followed by a shift toward a Th2
phenotype for the main duration of pregnancy and again a Th1
milieu toward partition (75). It should be noted, however, that
much of the data come from animal studies, which may not
necessarily reﬂect the human situation as in contrast to human
placentas, T cells represent a rare population in mouse pla-
centas (76).
Systemic immunological effects of pregnancy on IBD?
Diﬀerences in disease behavior between CD and UC during
pregnancy and peripartum may potentially be explained by in-
trinsic diﬀerences in the immune pathways that lead to each
disease. As seen above, pregnancy is associated with immuno-
logical changes at the fetal/maternal interface, with a pre-
dominantly Th2/tolerogenic phenotype. Thus, it is tempting to
speculate that a Th2 shift during pregnancy ameliorates disease in
those patients in whom Th1 responses dominate (such as CD),
while aggravating disease in Th2 dominant patients (mainly UC).
Nevertheless, the maternal peripheral immune system is still
capable of mounting a robust immune response to pathogenic
antigens (77), and the question therefore remains to what extent
placental immunological changes can aﬀect immunological
processes at distant body sites.
Levels of Th1 and Th2 patterns in utero generally appear to be
mirrored by ratios in peripheral blood (53), although most data
are derived from studies comparing pregnancy outcomes, and
hence blood is usually obtained at only one timepoint, often
postpartum. There are conﬂicting data on modulation of serum
cytokine levels in healthy pregnant women, with some studies
reporting a signiﬁcant decrease of proinﬂammatory Th1 cyto-
kines (e.g., IL-8, IL-12, IFN-g, and TNF-a) from ﬁrst to third
trimester in healthy pregnantwomen (78), and others showing no
diﬀerence or even an increase (79,80). For Th2 cytokines, even
less is known, with one study reporting a stable level of IL-4 and
IL-5 during pregnancy (81). Thus, it is unclear to what extent
pregnancy induces peripheral cytokine changes, which may in-
ﬂuence inﬂammatory diseases. However, ample evidence sug-
gests that peripheral blood cell subsets at least are altered in
normal pregnancy. For instance, stimulated peripheral blood
mononuclear cells from pregnant women produce less Th1 and
Th2 cytokines compared to healthy controls, in particular during
second trimester, whereas levels increased postpartum, suggest-
ing that systemic alterations in cell sensitivity exist during preg-
nancy, which may contribute to decreased (auto)immunity
during pregnancy and increased ﬂaring thereof, afterward (82).
The peripheral blood percentage of Tregs also peaks during the
second trimester of pregnancy, and in vitro, these Tregs are ca-
pable of reducing T-cell activation in response to DCs (83). Be-
cause development of Tregs during pregnancy appears to be
related to the presence of fetal alloantigens rather than pregnancy
hormones (84) and the Treg recognition receptor repertoire
diﬀers per organ (85), it is uncertain to what extent pregnancy-
induced circulating Tregs would be useful at the inﬂamed
mucosa. Nevertheless, much is unclear regarding mucosal Treg
antigen recognition (86), and the fact that peripheral blood Treg
levels drop during inﬂammation suggest that general recruitment
of Tregs to inﬂammatory sites occurs (42). Their presence there
may potentially contribute to modulation of inﬂammatory pro-
cesses through production of inhibitory cytokines or suppression
of DC maturation.
Similar to Tregs, NK cells present in preimplantation endo-
metrium show a diﬀerent receptor repertoire compared to pe-
ripheral blood NK cells in the same women (87). However, it
has also been reported that in the ﬁrst trimester of pregnancy,
progesterone-dependent expression of the receptor T cell
immunoglobulin and mucin-domain–containing-3 on peripheral
bloodNK cell confers immunosuppressive properties (88), and it is
conceivable that these cells also reach the intestinal mucosa where
they may modulate disease activity.
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Systemic effects of pregnancy hormones
The most important early immune modulator in pregnancy is
now acknowledged to be human chorionic gonadotropin (hCG),
which mediates early expansion of regulatory T cells (Tregs),
modulates DC responses by inducing IDO1 expression, and
reduces inﬂammatory cytokines such as IL-17 while increasing
IL-10 levels (89). Importantly, many of these eﬀects occur in
peripheral blood from nonpregnant patients receiving hCG for
their in vitro fertilization treatment. In vitro, hCG is able to
stimulate peripheral blood DC subsets to maintain a tolerant
phenotype (90). Several cleaved or “nicked” forms of hCG exist in
vivo, and studies have shown that such hCG peptides show anti-
inﬂammatory properties in a host of mouse models, including
lipopolysaccharides-induced septic shock, polymicrobial sepsis,
hemorrhagic shock, and diabetes (91–96). Administration of
hCG peptides also inhibited neutrophil recruitment and in-
ﬂammatory markers such as IL-6 and TNF-a (89,96,97). The
same authors also showed that human graft vs host disease at the
skin was successfully treated with hCG, which corresponded with
increased IDO1 expression in peripheral mononuclear cells, and
also IL-10 serum levels and Treg upregulation (98). With hCG
administration being able to prevent autoimmune diabetes in
mice by downregulating Th1 responses (99), the use of hCG to
control the autoimmune processes in RA and Sjogren’s disease
has been suggested (100), and it is tempting to speculate that hCG
may also positively aﬀect IBD.
The high amount of progesterone throughout pregnancy not
only results in the laxity of the ligaments and joints, but is also
thought to suppress the maternal immunologic response to fetal
antigens and allows implantation in the endometrium. Pro-
gesterone reduces proinﬂammatory mediators (i.e., TNF-a, IL-6,
IL-1b, and nitric oxide (NO)) and increases IL-10 production by
macrophages and monocytes (101). Application of progesterone
in a temporomandibular joint inﬂammation model of ovariec-
tomized rats reduced synovial inﬂammation and levels of TNF-a
and IL-1b (102). In a rat colitis model, progesterone amelio-
rated disease activity through reduction of TNF-a levels in
colon and blood (103). Nevertheless, conﬂicting data have
also been reported. In a chemically induced model of colitis
2,4,6-trinitrobenzene sulfonic acid, the progesterone domi-
nant luteal phase of the menstrual cycle was associated with in-
creased severity of colitis and treatment of ovariectomized animals
with progesterone similarly increased disease severity, whereas
estrogen decreased colitis (104). Indeed, anti-inﬂammatory prop-
erties have often been ascribed to estrogen, because it decreases
inﬂammatory cytokine production (i.e., TNF-a and IFN-g)
inhibits NO synthase activity and decreases the recruitment of
inﬂammatory cells (105,106). However, animal studies of IBD
and the eﬀect of estrogen also show inconsistent ﬁndings. Im-
provement of stool scores in human leukocyte antigen-B27
transgenic rats with chronic diarrhea was noted after treatment
with 17a-ethynyl-17b-EE (107). Similarly, estrogen reduced
TNF-a, IL-1b, and IL-6 levels, as well as inﬂammation in diverse
rat models of colitis (108). Verdu et al. (109) found that
a supraphysiological dose of 17b-EE has an anti-inﬂammatory
eﬀect in a dextran sodium sulfate murine model for colitis but
a proinﬂammatory eﬀect in the dinitrobenzene sulfonic acid
colitis model. Clinical human studies of IBD and sex hormones
focus mainly on postmenopausal women and/or oral contra-
ception use. Kane et al. (110) described a protective eﬀect of
estrogen on the bowel in women with IBD, whereas Khalili et al.
(111) showed that postmenopausal women who use oral con-
traceptives had a higher risk of developing UC, but not CD. A
meta-analysis of Cornish et al. (112) demonstrated that with
time of exposure to oral contraceptives, the risk of developing
CD was increased, and when contraceptives were stopped, the
risk decreased again to that of the normal population.
It is clear that there is conﬂicting data on IBD and levels of sex
hormones and that it is diﬃcult to translate these clinical studies
to the situation in a pregnant patient with IBD. Diﬀerent immune
cells may react in an opposite manner to diﬀerent concentrations
of estrogen and progesterone, and expression patterns of recep-
tors of these hormonesmay vary under inﬂammatory conditions,
precluding robust predictions on the overall eﬀect of pro-
gesterone and estrogen on autoimmune disease.
MICROBIOME IN IBD AND PREGNANCY
Asmentioned before, IBD is thought to arise in consequence of an
altered immune response toward intestinal bacteria. We now
know that the microbiome of patients with IBD is substantially
altered as compared to healthy controls, and that inﬂamed
regions show further microbial deregulation as compared to
noninﬂamed regions (113–115). This so-called dysbiosis includes
a reduced diversity of the bacteria present, in particular in patients
with CD, with a noted decrease of anti-inﬂammatory Firmicutes
(i.e., Faecalibacterium prausnitzii) and an increase of proteo-
bacteria and Bacteroidetes phylum members (i.e., Bacteroides
fragilis) (116–119). The host–microbiome interaction is re-
ciprocal, and it is as yet unclear whether dysbiosis in IBD presents
the chicken or the egg in the etiology of disease. Nevertheless, the
general consensus now favors a causative role for themicrobiome
in disease initiation, because animal models indicate that bacte-
rial presence is required for colitis development and that colitis
may be conferred by transplantation of inﬂammation-associated
feces (120).
Pregnancy is also accompanied by intestinal microbial
changes. These changes induce a metabolic state that may be
beneﬁcial during pregnancy, as concluded by Koren et al. (121).
They described that, in the ﬁrst trimester of pregnancy, the gut
microbiota is similar in many aspects to that of healthy non-
pregnant controls. However, in the third trimester, a dysbiosis
was observed, resembling a state of low-grade inﬂammation of the
gastrointestinal tract. This dysbiosis was accounted for by the
presence of Proteobacteria and Actinobacteria and was not re-
lated to body mass index (before pregnancy), antibiotic use, diet,
or the presence of gestational diabetes. The overall diversity of the
bacteria was also reduced at T3. These data would suggest that
microbial changes that occur during normal pregnancy fortify
dysbiotic changes seen in IBD, and would aggravate disease ac-
tivity. Interestingly, patients with CD show a less stable micro-
biome and reduced diversity compared to patients withUC (122),
and it is conceivable that further alterations during pregnancy
therefore have less of an eﬀect onCDdisease activity as compared
to UC. Of note, there are several studies which show that diet
shapes the microbiome, and in particular, western diets are as-
sociated with IBD (123,124). Because it is commonly appreciated
that women change their diet during pregnancy, it is important to
take this into account in future studies.
It is clear that while microbial changes during pregnancy and
the host defensemechanisms are both changed during pregnancy
and IBD, the interactions are complex, reciprocal, and double
edged, hampering interpretations of the observed changes.
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MICROCHIMERISM AND a-FETOPROTEIN
The placental exchange of maternal and fetal gases, nutrients,
metabolic waste products, and antibodies is well described. How-
ever, in addition to these small molecules, it is also possible for
whole cells to cross the placenta from mother to child and vice
versa. Suchcoexistenceof 2 genetically diﬀerent populations of cells
in one individual is termed (micro)chimerism. Cellular transport is
bidirectional (125,126), with maternal cells detected in 24%–42%
of fetal-derived samples, and fetal cells were detected in 26%–51%
ofmothers (127,128). Fetal cells, which can be detected as early as 7
weeks gestation, are known to persist for some time after delivery
(129). In fact, microchimerismhas been observed inmothers up to
38 years after pregnancy, and in oﬀspring well into adult life
(130,131). In addition to fetal mature T-cells, CD341 progenitor
cells enter the maternal bloodstream during pregnancy, which
retain their multilineage potential and can become adult hemato-
poietic cells of all linages and epithelial cells (131,132). With the
potential for these cells to assert eﬀector functions and aﬀect the
maternal immune system, the functional immunological con-
sequences of these microchimers in health and disease are gaining
interest (133,134). Male fetal cell-derived T-cell clones isolated
from parous women show proliferation and IL-4 production in
response to ex vivo stimulation with maternal T cells and MHC
antigens, and this eﬀect was higher in patients with systemic scle-
rosis, suggesting that these oﬀspring T cells show a Th2 proﬁle and
could play a pathogenic role in immune disease (135). In-
terestingly, increased microchimerism was observed in peripheral
blood mononuclear cells from patients with the autoimmune dis-
ease scleroderma, which has a peak incidence in women after
childbearing years, again suggesting that such microchimerism
may contribute in autoimmune disease (131). However, patients
with either Grave’s disease or Hashimoto’s thyroiditis, two other
autoimmune diseases associated with pregnancy, have reduced
microchimerism as compared to healthy controls (136). Further-
more, microchimerism has been investigated in systemic lupus
erythematosus (SLE), Sjogren’s syndrome, multiple sclerosis, and
RA, and may be either protective or harmful (133). In RA, where
there is a clear beneﬁcial eﬀect of pregnancy on disease course, it
had been suggested that accumulation of fetal T cells, which appear
around gestational week 13, may dampen the maternal immune
response, and that this eﬀect weakens over time, because of se-
nescence of these cells (137). The presence of fetal cells inmaternal
tissues correlates to the presence of maternal Tregs, which may
account for someof the dampeningof inﬂammatorydisease during
pregnancy (134). Although the exact eﬀect of microchimerism on
(auto)immune disease is as yet unclear, it is tempting to speculate
that it may also play a role in IBD and aﬀect disease course during
pregnancy. Thus far, only maternal microchimerism has been
studied in IBD, which did not appear to be increased in patients
with IBD (138,139). Fetal microchimerism in IBD pregnancy
remains to be investigated.
Another potential fetal source contributing to maternal (auto)
immune response is a-fetoprotein (AFP), a protein produced by
the yolk sac and fetal liver, which can be detected in the maternal
serum fromweek 14 of pregnancy onward. AFPwas shown to bind
to autoantibodies produced in patients with the autoimmune dis-
order myasthenia gravis (MG), and it was thus speculated that
circulating levels of AFP in the second and third trimester of
pregnancy could induce clinical remission in patients with myas-
thenia gravis during these times (140). The immunomodulatory
eﬀects of AFP extend beyond antibody binding (141). Studies in-
dicate that AFP ameliorates a mouse model of multiple sclerosis
(MS), through, among others, inhibition of Th1 cytokine pro-
duction (142). It has been speculated that AFPmay be used for the
treatment of myasthenia gravis, MS, autoimmune uveitis, and
psoriasis (143). Thus far, however, the potential role of AFP in IBD
remains unexplored.
MODULATION OF IBD RESPONSE TO MEDICATION
THROUGH PREGNANCY
Disease activity in women with IBD may also be modulated by
pharmacokinetic changes induced by pregnancy and through
interaction of IBD medication with the placenta, which may
modulate the clinical eﬀectivity of these drugs. However, al-
though drugs such as the thiopurine 6-thioguanine nucleotide
and 5-aminosalicylic acid are known to cross the placenta, this
does not seem to inﬂuence therapeutic levels in the mothers
(144). Less is known about the eﬀects on patient and child
outcomes of biologicals, the most recent IBD medications. The
earliest of these are the anti-TNF-a treatments (inﬂiximab,
adalimumab, golimumab, and certolizumab pegol), with
vedolizumab (a4b7 integrin blocker) and ustekinumab (IL-12/
IL-23 blocker) following suit. From week 20 onward, maternal
immunoglobulins (Igs) are transported across the placental
barrier, to provide immunoprotection to the fetus (145).
Transport of Igs is mediated by the neonatal fragment crystal-
lizable (Fc) receptor (FcRn), which binds to the Fc region
present in all antibodies, including therapeutic monoclonal
antibodies. Certolizumab pegol does not undergo this FcRn-
mediated transfer across the placenta, because it lacks an IgG Fc
region and therefore does not bind FcRn. Owing to the passive
diﬀusion across the placenta, the levels of certolizumab pegol
reaching the fetus are probably much lower when compared to
inﬂiximab and adalimumab (146). We and others have pre-
viously shown that inﬂiximab and adalimumab levels in cord
blood exceed levels present in serum frommothers treated with
these medications (147,148), suggesting that active transport of
these antibodies over the placental barrier may decrease bio-
availability of the antibodies in themother. As serumdrug levels
of these therapeutic antibodies correspond to clinical outcomes
for patients with IBD, modulation of these levels through pla-
cental transport could potentially result in disease relapse
(149,150). Thus far, however, maternal inﬂiximab levels during
pregnancy were shown to be increased, whereas adalimumab
levels remained stable. Nevertheless, pharmacokinetic changes
of these therapeutic antibodies on pregnancy have only been
studied in a small cohort of patients, and larger studies are
needed (151).
SUMMARY
The observation that the disease course of several (auto)immune
diseases are altered during pregnancy suggests that there is an
interaction between physiological changes taking place during
pregnancy and pathophysiology of these diseases (Figure 1). For
IBD, this relationship appears more apparent for UC than CD,
which may be due to the fact that CD and UC have diﬀerential
underlying genetic susceptibilities, immune proﬁles, and micro-
bial changes. Genetic variants aﬀecting cellular innate immunity
are associated more with CD, whereas UC-speciﬁc single nucle-
otide polymorphisms aﬀect epithelial barrier function genes
(152). Furthermore, patientswithCDshowamoreTh1 dominant
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cytokine proﬁle and less stable microbiome compared to patients
with UC, where Th2 responses appear more prevalent. Pregnancy
modulates these disease-underlying mechanisms to a diﬀerent
extent at diﬀerent timepoints during gestation, whichmay further
explain why disease modiﬁcation is not always apparent. Never-
theless, several conclusions may be inferred from our current
understanding of pregnancy-induced physiological changes.
Overall, a beneﬁcial eﬀect of pregnancy on epithelial barrier
function seems apparent, with relatively small ﬂuctuations of
pregnancy hormones already aﬀecting the gut barrier. Further-
more, an overall image of induction of tolerance and suppression
of immune responses during gestation is arising. With a pre-
dominant shift toward a Th2 phenotype, many reviews have
speculated that, in particular, Th1-mediated diseases such as RA
and CD may beneﬁt from these pregnancy-induced changes,
whereas Th2-mediated diseases (such as SLE and UC) might be
negatively aﬀected (6,153,154). HCG, estrogen, and progesterone
rise rapidly during pregnancy and have shown several anti-
inﬂammatory actions in animal models. Although most of these
changeswould be compatiblewith improvement of IBD activity, it
has also been demonstrated that pregnant patients with SLE have
lower levels of estrogen and progesterone in the third trimester of
pregnancy compared to healthy controls, suggesting that some
patient groupsmay beneﬁt less from rises in pregnancy hormones
(155). This alsomight be the case inUC, but studies to support this
hypothesis are lacking. Finally, changes in the microbiome oc-
curring during normal pregnancy do not appear to be beneﬁcial to
patients with IBD, but again, it is unclear to what extent these
changes are modulated by pregnancy hormones and to what ex-
tent microbial alterations are present in pregnant patients with
IBD. Thus, immune regulation in both pregnancy and IBD are
complicated and not static. Whether or not IBD course is aﬀected
by pregnancy may depend on individual patient’s characteristics,
including ongoing disease activity before conception, their
microbiome and hormone/diet-induced changes therein, and
genetic underlying risk factors. Predicting which patients may
experience reduced disease burden or increased disease activity
during pregnancy and postpartum requires a better insight into
the physiology and pathology of pregnancy and IBD.
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